Calyxo vs Doximity
Side-by-side comparison of AI visibility scores, market position, and capabilities
Calyxo is a urology medical device company developing CVAC, a vacuum-assisted catheter for kidney stone fragment retrieval; raised $80M Series C in 2023;
About
Calyxo is a medical device company founded in 2017 and headquartered in Pleasanton, California, focused on improving outcomes in kidney stone treatment. The company's lead product is the CVAC System (Calyxo Vacuum-Assisted Catheter), an FDA-cleared ureteroscopy tool that uses suction to vacuum out kidney stone fragments during a single minimally invasive procedure. Traditional stone removal with a basket retrieval device requires multiple passes and often leaves residual fragments — a problem Calyxo's system addresses by continuously aspirating debris as the laser breaks up stones, achieving substantially higher stone-free rates in a single operating room session.
Doximity (NYSE: DOCS), professional network for US physicians with 2M+ verified clinicians; telehealth, medical news, and career tools monetized via pharmaceutical digital marketing.
About
Doximity is a professional network and digital health platform purpose-built for licensed physicians and other healthcare professionals in the United States. With more than two million verified clinicians on the platform — representing the majority of practicing US physicians — Doximity has established itself as the dominant professional network for doctors, providing identity-verified peer connections, specialty-specific news feeds, medical journal access, and career management tools including a physician job board and CV builder. The verification layer distinguishes Doximity from general professional networks and makes it the standard reference for confirming physician credentials and contact information across the healthcare industry.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.